
Keywords: Sinusoidal obstruction syndrome; Colorectal liver metastases; Bevacizumab; Oxaliplatin; Splenic volumeCRLM, colorectal liver metastases; OX, oxaliplatin; FU, fluorouracil; LV, leucovorin; SOS, sinusoidal obstruction syndrome; Bmab, bevacizumab; VEGF, vasc